<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103569</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-016</org_study_id>
    <nct_id>NCT02103569</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325</brief_title>
  <official_title>Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose
      combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive
      agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND Number: 79,599 and 101,943

      Other: Phase 1 Clinical Pharmacology drug interaction study in healthy female subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone</measure>
    <time_frame>Day 21 to Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone</measure>
    <time_frame>Day 21 to Day 49</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of Ethinyl Estradiol and Norethindrone</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by occurrence of Adverse events (AEs), serious AEs and AEs leading to discontinuation</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by abnormalities in vital sign measurements</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by findings on Electrocardiogram (ECG) measurements and physical examinations</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by marked abnormalities in clinical laboratory test results</measure>
    <time_frame>Day 1 to Day 50</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days
Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC of Daclatasvir, Asunaprevir and BMS-791325</intervention_name>
    <arm_group_label>Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC of Norethindrone and Ethinyl Estradiol</intervention_name>
    <arm_group_label>Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325</arm_group_label>
    <other_name>LoestrinÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy females within age of 18-40 years

          -  Must be a Women of Childbearing potential

          -  Must be on a stable regimen of oral contraceptive therapy for at least 3 consecutive
             months prior to study start

        Exclusion Criteria:

          -  Subjects must not have any significant acute or chronic medical illnesses or
             conditions precluding safe use of oral contraceptives

          -  Prior exposure to DCV, ASV or BMS-791325 within 30 days of dosing on study day 1

          -  Smoking within 6 months of study start
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

